Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancerMyrto Moutafi, David L. Rimm, Charles T. Robbins et al.|Laboratory Investigation|2022Cited by 141
Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarraySandra Martínez-Morilla, David L. Rimm|Laboratory Investigation|2019Cited by 66
Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass CytometrySandra Martínez-Morilla, David L. Rimm|Clinical Cancer Research|2021Cited by 62
Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial ProfilingMyrto Moutafi, David L. Rimm, Aileen I. Fernandez et al.|Journal of Thoracic Oncology|2022Cited by 40
Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithmsThazin Nwe Aung, David L. Rimm, Saba Shafi et al.|EBioMedicine|2022Cited by 33